Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Kwon O-, Zhang B, Jia D, Zhang L, Wei X, Zhou Z, et al. Elevated expression of the colony-stimulating factor 1 (CSF1) induces prostatic intraepithelial neoplasia dependent of epithelial-Gp130. Oncogene. 2022;41(9):1309-1323.

Lally L, Narula N, Goodfellow N, Luqmani R, Pisapia D, Spiera RF. Rho Kinase Expression in Giant Cell Arteritis: Validating Phosphorylated Ezrin/Radixin/Moesin Intensity Score to Increase Sensitivity of Temporal Artery Biopsy. J Rheumatol. 2022;49(8):908-912.

Brendel M, Getseva V, Assaad MA, Sigouros M, Sigaras A, Kane T, et al. Weakly-supervised tumor purity prediction from frozen H&E stained slides. EBioMedicine. 2022;80:104067.

Choi SY, Ribeiro CF, Wang Y, Loda M, Plymate SR, Uo T. Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer. Biomolecules. 2022;12(11).

Guo P, Liu Y, Geng F, Daman AW, Liu X, Zhong L, et al. Publisher Correction: Histone variant H3.3 maintains adult haematopoietic stem cell homeostasis by enforcing chromatin adaptability. Nat Cell Biol. 2022;24(2):279.

Linares JF, Cid-Diaz T, Duran A, Osrodek M, Martinez-Ordoñez A, Reina-Campos M, et al. The lactate-NAD+ axis activates cancer-associated fibroblasts by downregulating p62. Cell Rep. 2022;39(6):110792.

Bégin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, et al. Author Correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med. 2022;28(1):212.

Coan BG, Cesarman E, Acencio ML, de Oliveira DE. Latent Membrane Protein 1 (LMP1) from Epstein-Barr Virus (EBV) Strains M81 and B95.8 Modulate miRNA Expression When Expressed in Immortalized Human Nasopharyngeal Cells. Genes (Basel). 2022;13(2).

Zhao Z, Yang HS. Robust antibody response in children to acute COVID-19 infection and lasts for months. J Pediatr. 2022;240:310-313.

Snyder EL, Wheeler AP, Refaai M, Cohn CS, Poisson J, Fontaine M, et al. Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet components. Transfusion. 2022;62(7):1365-1376.